시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 요로상피암 치료 시장 보고서(2025년)
Urothelial Carcinoma Treatment Global Market Report 2025
상품코드 : 1695224
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,339,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,163,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,987,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

요로상피암 치료 시장 규모는 향후 몇 년 동안 연평균 16.5%의 성장률(CAGR)로 2029년까지 62억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 인구 고령화, 맞춤형 의료에 대한 수요, 요로상피암 연구 및 치료에 대한 정부 지원 증가, 요로상피암 치료에 대한 투자 증가에 기인합니다. 예측 기간 동안 주요 동향은 바이오마커 기반 치료, 신보조 및 보조 접근법, 액체 생검, 최소침습수술, 화학요법 개발, 디지털 헬스 기술 등입니다.

방광암 발병률 증가는 향후 요로상피암 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 방광암은 방광을 덮고 있는 세포를 침범하는 흔한 암으로, 환자와 의료진에게 다양한 치료 옵션의 필요성이 대두되고 있습니다. 방광암에 대한 연구는 표적 치료에 대한 정보를 제공하고, 요로상피암에 대한 이해를 높이고, 치료 결과를 개선하기 위한 다학제적 접근을 촉진하는 데 도움이 될 것입니다. 예를 들어, 2023년 9월 미국 연방정부가 운영하는 의학도서관인 국립의학도서관은 2040년까지 신규 방광암(BCa) 환자 수가 2020년 대비 72.8% 증가한 99만1,000명에 달할 것으로 예측했습니다. 또한, BCa 관련 연간 사망자 수는 397,000명에 달해 86.6% 증가할 것으로 예상했습니다. 이에 따라 방광암 발병률 증가가 요로상피암 치료제 시장을 견인할 것으로 보입니다.

화학요법에 대한 수요 증가는 당분간 요로상피암 치료 시장 성장의 중요한 촉진제가 될 것으로 예상됩니다. 화학요법은 체내에서 빠르게 분열하는 세포를 표적으로 삼고 이를 박멸하기 위해 약물을 사용하는 치료법으로, 일반적으로 암 치료에 채택되고 있습니다. 화학요법의 매우 중요한 역할은 질병의 다양한 단계를 관리하는 효과로 인해 요로상피암 치료에서 필수적인 접근법이 되었습니다. 예를 들어, 미국에 본사를 둔 의료 정보 제공업체인 Mesothelioma.com에 따르면, 2023년 6월 현재 미국 암 환자의 약 25%가 매년 화학요법을 받고 있다고 합니다. 따라서 화학요법에 대한 수요 증가는 요로상피암 치료 시장을 촉진할 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Urothelial carcinoma is a form of cancer that originates in the urothelial cells lining the interior of the urinary system, encompassing the bladder, ureters (connecting tubes between the kidneys and the bladder), and the renal pelvis (the kidney segment responsible for collecting urine). Treatments for urothelial carcinoma, involving both surgical procedures and intravenous therapies, play a crucial role in managing the disease, enhancing patient outcomes, and improving their quality of life.

The primary categories of urothelial carcinoma treatment are non-invasive and invasive. Non-invasive treatment pertains to addressing early-stage bladder cancer that has not spread to the deeper layers of the bladder or surrounding tissues. This is achieved through techniques like transurethral resection of bladder tumors (TURBT), which entails the removal of cancerous tissue from the bladder lining, and intravesical therapies, where medications are directly delivered into the bladder to prevent recurrence. These treatments, encompassing immunotherapy, radiotherapy, and chemotherapy, are also employed to address various types of urinary system cancers, including bladder, urethral, ureteric, and renal pelvic cancers. These treatments serve a variety of end users, including hospitals, homecare services, specialty centers, and others.

The urothelial carcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides urothelial carcinoma treatment market statistics, including urothelial carcinoma treatment industry global market size, regional shares, competitors with a urothelial carcinoma treatment market share, detailed urothelial carcinoma treatment market segments, market trends and opportunities and any further data you may need to thrive in the urothelial carcinoma treatment industry. This urothelial carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urothelial carcinoma treatment market size has grown rapidly in recent years. It will grow from $2.86 billion in 2024 to $3.37 billion in 2025 at a compound annual growth rate (CAGR) of 18.0%. The growth in the historic period can be attributed to rising prevalence of urothelial carcinoma, growing awareness of urothelial carcinoma, increasing access to healthcare, rising disposable incomes.

The urothelial carcinoma treatment market size is expected to see rapid growth in the next few years. It will grow to $6.22 billion in 2029 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to aging population, demand for personalized medicine, rising government support for urothelial carcinoma research and treatment, growing investments on urothelial carcinoma treatment. Major trends in the forecast period include biomarker-driven therapies, neoadjuvant and adjuvant approaches, liquid biopsies, minimally invasive surgeries, chemotherapy development, digital health technologies.

The growing incidence of bladder cancer is expected to drive the expansion of the urothelial carcinoma treatment market in the future. Bladder cancer is a common cancer that affects the cells lining the urinary bladder, leading to the need for a variety of treatment options for patients and healthcare providers. Research into bladder cancer helps inform targeted therapies and enhances understanding of urothelial carcinoma, promoting cross-disciplinary approaches to improve treatment outcomes. For example, in September 2023, the National Library of Medicine, a U.S.-based medical library operated by the federal government, projected that the number of new bladder cancer (BCa) cases would reach 991,000 by 2040, reflecting a 72.8% increase from 2020. Annual BCa-related deaths are also expected to rise to 397,000, marking an 86.6% increase. As a result, the growing incidence of bladder cancer will drive the urothelial carcinoma treatment market.

The growing demand for chemotherapy is anticipated to be a significant driver for the growth of the urothelial carcinoma treatment market in the foreseeable future. Chemotherapy is a medical treatment that employs drugs to target and eradicate rapidly dividing cells within the body, commonly employed in cancer treatment. Chemotherapy's pivotal role stems from its effectiveness in managing various stages of the disease, making it an integral approach in urothelial carcinoma treatment. For instance, as of June 2023, Mesothelioma.com, a medical information provider based in the United States, reports that approximately 25% of cancer patients in the US receive chemotherapy each year. Hence, the increasing demand for chemotherapy is set to propel the urothelial carcinoma treatment market.

The prominent companies operating in the urothelial carcinoma treatment market are actively dedicated to introducing innovative products to enhance their competitive positions and meet the changing needs of their customers. For example, in March 2023, Nonacus Limited, a UK-based medical product manufacturer, unveiled GALEAS Bladder, a cutting-edge diagnostic test designed for the non-invasive detection of bladder cancer. GALEAS Bladder represents a significant advancement in bladder cancer diagnostics, offering a comprehensive molecular triage solution that seamlessly moves from sample collection to the final diagnostic report. It leverages a molecular biomarker with exceptional sensitivity to quickly and accurately identify bladder cancer, simplifying the diagnostic process and reducing the necessity for invasive procedures like cystoscopies. Developed in partnership with the University of Birmingham in the UK, GALEAS Bladder has undergone rigorous validation, involving over 600 patient samples from three distinct clinical cohorts in the UK. This extensive assessment underscores the remarkable performance of GALEAS Bladder, delivering high diagnostic accuracy (with a sensitivity exceeding 90% and specificity over 85%) and effectively catering to varying bladder cancer grades and stages.

In September 2024, A. Menarini Diagnostics, an Italy-based pharmaceutical company, entered into a partnership with Nucleix to enhance product marketing. As part of this collaboration, A. Menarini Diagnostics will assume exclusive marketing rights for the non-invasive Bladder EpiCheck test across Europe in the coming months. This urine test will provide patients and clinicians with an effective tool for detecting and monitoring the recurrence of bladder cancer and upper tract urothelial carcinoma (UTUC). Nucleix, an Israel-based company, specializes in the development and sale of non-invasive cancer tests.

Major companies operating in the urothelial carcinoma treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Inc., GlaxoSmithKline PLC, Astellas Pharma Inc., Agilent Technologies Inc., Eisai Co. Ltd., Incyte Corporation, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Seagen Inc., Lupin Limited, Genentech Inc., UroGen Pharma Inc., Acerta Pharma B.V., Asieris Pharmaceuticals Co. Ltd., Pacific Edge Limited, Protara Therapeutics Inc., Hamlet Pharma AB, CG Oncology Inc., AroCell AB, ImmunityBio Inc., IDL Biotech AB.

North America was the largest region in the urothelial carcinoma treatment market in 2024. The regions covered in urothelial carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the urothelial carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urothelial carcinoma treatment market consists of revenues earned by entities by providing transurethral resection (TURBT) surgery and external beam radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The urothelial carcinoma treatment market also includes sales of platinum-based chemotherapy drugs such as cisplatin or carboplatin and immune checkpoint inhibitor drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urothelial Carcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urothelial carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for urothelial carcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urothelial carcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Urothelial Carcinoma Treatment Market Characteristics

3. Urothelial Carcinoma Treatment Market Trends And Strategies

4. Urothelial Carcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Urothelial Carcinoma Treatment Growth Analysis And Strategic Analysis Framework

6. Urothelial Carcinoma Treatment Market Segmentation

7. Urothelial Carcinoma Treatment Market Regional And Country Analysis

8. Asia-Pacific Urothelial Carcinoma Treatment Market

9. China Urothelial Carcinoma Treatment Market

10. India Urothelial Carcinoma Treatment Market

11. Japan Urothelial Carcinoma Treatment Market

12. Australia Urothelial Carcinoma Treatment Market

13. Indonesia Urothelial Carcinoma Treatment Market

14. South Korea Urothelial Carcinoma Treatment Market

15. Western Europe Urothelial Carcinoma Treatment Market

16. UK Urothelial Carcinoma Treatment Market

17. Germany Urothelial Carcinoma Treatment Market

18. France Urothelial Carcinoma Treatment Market

19. Italy Urothelial Carcinoma Treatment Market

20. Spain Urothelial Carcinoma Treatment Market

21. Eastern Europe Urothelial Carcinoma Treatment Market

22. Russia Urothelial Carcinoma Treatment Market

23. North America Urothelial Carcinoma Treatment Market

24. USA Urothelial Carcinoma Treatment Market

25. Canada Urothelial Carcinoma Treatment Market

26. South America Urothelial Carcinoma Treatment Market

27. Brazil Urothelial Carcinoma Treatment Market

28. Middle East Urothelial Carcinoma Treatment Market

29. Africa Urothelial Carcinoma Treatment Market

30. Urothelial Carcinoma Treatment Market Competitive Landscape And Company Profiles

31. Urothelial Carcinoma Treatment Market Other Major And Innovative Companies

32. Global Urothelial Carcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Urothelial Carcinoma Treatment Market

34. Recent Developments In The Urothelial Carcinoma Treatment Market

35. Urothelial Carcinoma Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기